NSCLC (Issue 10) | Special Reports

Dr. Geoffrey R. Oxnard Treating EGFR-Inhibitor Resistant Patients With Lung Cancer

January 18, 2016

Clinical Articles

Geoffrey R. Oxnard, MD, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.

Marianne Davies, NP, on Assessing Immunotherapy Toxicities in Lung Cancer Patients

January 18, 2016

Clinical Articles

Marianne Davies, NP, discusses making patients' oncology team their first line of contact should they develop any toxicities related to receiving treatment. Davies says this is important for patients so that the oncology team can assess whether it is an immune-related side effect, or an issue that can be dealt with by their primary care physician.

Research Team Challenges Plant-Derived Molecule for the Treatment of NSCLC

January 14, 2016

Clinical Articles

A team from the Scripps Research Institute and Bristol-Myers Squibb recently collaborated to collectively develop a method for complete chemical synthesis of antroquinonol and to test the biologic activity of the chemically synthesized product. Contrary to previous reports, the study reported minimal in vitro and in vivo antitumor activity of chemically synthesized antroquinonol A.

Combining Immunotherapy With Anti-VEGF Agents Rigorously Explored in NSCLC

January 13, 2016

Clinical Articles

The success of the immunotherapies pembrolizumab and nivolumab for the treatment of non-small cell lung cancer (NSCLC), and the promising results in NSCLC for the investigational agent atezolizumab, have generated an interest in new combinations with other agents

Lung Cancer Incidence and Mortality Review Shows No Ethnic Differences in Women

January 07, 2016

Clinical Articles

There are no differences in lung cancer incidence or mortality among women of different ethnic groups when adjusted for age, smoking, and other factors, according to an article recently published in the Journal of Clinical Oncology.